跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,659 条关于
“Antengene Corporation”
全部
1,659
临床试验
141
药物
96
机构
468
资讯
954
去年
Antengene's Xpovio Receives Thailand FDA Approval for Multiple Myeloma
去年
XPOVIO® (Selinexor) Included in China's National Reimbursement Drug List for R/R DLBCL
去年
Antengene to Present Selinexor Data in Relapsed/Refractory Multiple Myeloma and Extranodal NK/T-Cell Lymphoma at ASH 2024
去年
Antengene's Selinexor Shows Promise in Multiple Myeloma and Lymphoma Studies
去年
Antengene to Present Selinexor Data from Late-Stage Trials at ASH 2024
去年
Antengene to Present Selinexor Data from Two Late-Stage Studies at ASH 2024
去年
Antengene to Present Selinexor Data from Phase III Multiple Myeloma and Phase I/II Lymphoma Studies at ASH 2024
6个月前
UCB Secures $1.1B License for Antengene's Masked T-Cell Engager ATG-201 in Autoimmune Disease Push
9个月前
Antengene Receives NMPA Approval for Phase Ib/II Study of ATG-022 CLDN18.2 ADC in Combination with Pembrolizumab for Gastric Cancer
去年
FDA Issues Second Rejection for Rivoceranib/Camrelizumab Combination in Unresectable Liver Cancer
第 1 页,共 96 页
上一页
下一页